Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment

Circulation

Volumn 117, Issue 23, 2008, Pages 3002-3009

  Kastelein, John J P ^a,i   Van Der Steeg, Wim A ^a   Holme, Ingar ^b   Gaffney, Michael ^c   Cater, Nilo B ^c   Barter, Philip ^d   Deedwania, Prakash ^e   Olsson, Anders G ^f   Boekholdt, S Matthijs ^a   Demicco, David A ^c   Szarek, Michael ^c   Larosa, John C ^g   Pedersen, Terje R ^b   Grundy, Scott M ^h  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^c PFIZER INC   (United States)

^d HEART RESEARCH INSTITUTE   (Australia)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^g SUNY DOWNSTATE MEDICAL CENTER   (United States)

^h UNIVERSITY OF TEXAS AT DALLAS   (United States)

ⁱ Department of Vascular Medicine ^*  (Netherlands)

Author keywords

Apolipoproteins; Cardiovascular diseases; Cholesterol; Myocardial infarction; Prevention

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; STATIN; TRIACYLGLYCEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID;

ADULT; ARTICLE; CARDIAC PATIENT; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; DOSE RESPONSE; FEMALE; HUMAN; ISCHEMIC HEART DISEASE; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; STATISTICAL MODEL; TRIACYLGLYCEROL BLOOD LEVEL; AGED; BLOOD; CORONARY ARTERY DISEASE; DYSLIPIDEMIA; FACTUAL DATABASE; MIDDLE AGED; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL; RISK;

AGED; APOLIPOPROTEIN A-I; APOLIPOPROTEINS B; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CORONARY DISEASE; DATABASES, FACTUAL; DYSLIPIDEMIAS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPIDS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK; TRIGLYCERIDES;

EID: 46449096115     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.107.713438     Document Type: Article

References (39)

1. Yusuf S, Reddy S, Ounpuu S, Anand S. Global burden of cardiovascular diseases: part I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization. Circulation. 2001;104:2746-2753.
2. Murray CJL, Lopez AD, eds. The Global Burden of Disease: A Comprehensive Assessment of Mortality and Disability from Diseases, Injuries and Risk Factors in 1990 and Projected to 2020. Boston: Mass: Harvard School of Public Health; 1996.
3. Castelli WP, Anderson K, Wilson PW, Levy D. Lipids and risk of coronary heart disease: the Framingham Study. Ann Epidemiol. 1992;2:23-28.
4. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R, Simes R. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet. 2005;366: 1267-1278.
5. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106: 3143-3421.
6. Gotto AM Jr, Whitney E, Stein EA, Shapiro DR, Clearfield M, Weis S, Jou JY, Langendorfer A, Beere PA, Watson DJ, Downs JR, de Cani JS. Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Circulation. 2000;101: 477-484.
7. Simes RJ, Marschner IC, Hunt D, Colquhoun D, Sullivan D, Stewart RAH, Hague W, Keech A, Thompson P, White H, Shaw J, Tonkin A. Relationship between lipid levels and clinical outcomes in the Long-Term Intervention With Pravastatin in Ischemic Disease (LIPID) Trial: to what extent is the reduction in coronary events with pravastatin explained by on-study lipid levels? Circulation. 2002;105:1162-1169.
8. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, Gotto AM, Greten H, Kastelein JJP, Shepherd J, Wenger NK; the Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352:1425-1435.
9. Pedersen TR, Faergeman O, Kastelein JJP, Olsson AG, Tikkanen MJ, Holme I, Larsen ML, Bendiksen FS, Lindahl C, Szarek M, Tsai J; for the Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) Study Group. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA. 2005;294:2437-2445.
10. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499-502.
11. Albers JJ, Marcovina SM, Kennedy H. International Federation of Clinical Chemistry standardization project for measurements of apolipoproteins A-I and B, II: evaluation and selection of candidate reference materials. Clin Chem. 1992;38:658-662.
12. Rawlings JO, Pantula SG, Dickey DA. Applied Regression Analysis: A Research Tool. New York, NY: Springer-Verlag; 1998.
13. Rallidis LS, Pitsavos C, Panagiotakos DB, Sinos L, Stefanadis C, Kremastinos DT. Non-high density lipoprotein cholesterol is the best discriminator of myocardial infarction in young individuals. Atherosclerosis. 2005;179:305-309.
14. Liu J, Sempos CT, Donahue RP, Dorn J, Trevisan M, Grundy SM. Non-high-density lipoprotein and very-low-density lipoprotein cholesterol and their risk predictive values in coronary heart disease. Am J Cardiol. 2006;98:1363-1368.
15. Bittner V, Hardison R, Kelsey SF, Weiner BH, Jacobs AK, Sopko G. Non-high-density lipoprotein cholesterol levels predict five-year outcome in the Bypass Angioplasty Revascularization Investigation (BARI). Circulation. 2002;106:2537-2542.
16. von Mühlen D, Langer RD, Barrett-Connor E. Sex and time differences in the associations of non-high-density lipoprotein cholesterol versus other lipid and lipoprotein factors in the prediction of cardiovascular death (the Rancho Bernardo Study). Am J Cardiol. 2003;91:1311-1315.
17. Farwell WR, Sesso HD, Buring JE, Gaziano JM. Non-high-density lipoprotein cholesterol versus low-density lipoprotein cholesterol as a risk factor for a first nonfatal myocardial infarction. Am J Cardiol. 2005;96: 1129-1134.
18. Ridker PM, Rifai N, Cook NR, Bradwin G, Buring JE. Non-HDL cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women. JAMA. 2005;294:326-333.
19. Pischon T, Girman CJ, Sacks FM, Rifai N, Stampfer MJ, Rimm EB. Non-high-density lipoprotein cholesterol and apolipoprotein B in the prediction of coronary heart disease in men. Circulation. 2005;112: 3375-3383.
20. Everett BM, Kurth T, Buring JE, Ridker PM. The relative strength of C-reactive protein and lipid levels as determinants of ischemic stroke compared with coronary heart disease in women. J Am Coll Cardiol. 2006;48:2235-2242.
21. Walldius G, Jungner I, Holme I, Aastveit AH, Kolar W, Steiner E. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet. 2001;358:2026-2033.
22. St-Pierre AC, Cantin B, Dagenais GR, Despres JP, Lamarche B. Apolipoprotein-B, low-density lipoprotein cholesterol, and the long-term risk of coronary heart disease in men. Am J Cardiol. 2006;97:997-1001.
23. Benn M, Nordestgaard BG, Jensen GB, Tybjaerg-Hansen A. Improving prediction of ischemic cardiovascular disease in the general population using apolipoprotein B: the Copenhagen City Heart Study. Arterioscler Thromb Vasc Biol. 2007;27:661-670.
24. Hsia SH, Pan D, Berookim P, Lee ML. A population-based, cross-sectional comparison of lipid-related indexes for symptoms of atherosclerotic disease. Am J Cardiol. 2006;98:1047-1052.
25. Shai I, Rimm EB, Hankinson SE, Curhan G, Manson JE, Rifai N, Stampfer MJ, Ma J. Multivariate assessment of lipid parameters as predictors of coronary heart disease among postmenopausal women: potential implications for clinical guidelines. Circulation. 2004;110: 2824-2830.
26. Van der Steeg W, Boekholdt S, Stein E, El-Harchaoui K, Stroes E, Sandhu M, Wareham N, Jukema J, Luben R, Zwinderman A, Kastelein J, Khaw K. Role of the apolipoprotein B-AI ratio in cardiovascular risk assessment: a case-control analysis in the EPIC-Norfolk Study. Ann Intern Med. 2007;146:1-10.
27. Ingelsson E, Schaefer EJ, Contois JH, McNamara JR, Sullivan L, Keyes MJ, Pencina MJ, Schoonmaker C, Wilson PW, D'Agostino RB, Vasan RS. Clinical utility of different lipid measures for prediction of coronary heart disease in men and women. JAMA. 2007;298:776-785.
28. The Lipid Research Clinics Program Epidemiology Committee. Plasma lipid distributions in selected North American populations: the Lipid Research Clinics Program Prevalence Study. Circulation. 1979;60:427-439.
29. Abate N, Vega GL, Grundy SM. Variability in cholesterol content and physical properties of lipoproteins containing apolipoprotein B-100. Atherosclerosis. 1993;104:159-171.
30. Elovson J, Chatterton JE, Bell GT, Schumaker VN, Reuben MA, Puppione DL, Reeve JR Jr, Young NL. Plasma very low density lipoproteins contain a single molecule of apolipoprotein B. J Lipid Res. 1988;29:1461-1473.
31. Chapman MJ, Laplaud PM, Luc G, Forgez P, Bruckert E, Goulinet S, Lagrange D. Further resolution of the low density lipoprotein spectrum in normal human plasma: physicochemical characteristics of discrete subspecies separated by density gradient ultracentrifugation. J Lipid Res. 1988;29:442-458.
32. Deedwania P, Barter P, Carmena R, Fruchart JC, Grundy SM, Haffner S, Kastelein JJ, LaRosa JC, Schachner H, Shepherd J, Waters DD. Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study. Lancet. 2006;368:919-928.
33. Lee JY, Parks JS. ATP-binding cassette transporter AI and its role in HDL formation. Curr Opin Lipidol. 2005;16:19-25.
34. Fielding CJ, Shore VG, Fielding PE. Lecithin:cholesterol acyltransferase: effects of substrate composition upon enzyme activity. Biochim Biophys Acta. 1972;270:513-518.
35. Navab M, Hama SY, Anantharamaiah GM, Hassan K, Hough GP, Watson AD, Reddy ST, Sevanian A, Fonarow GC, Fogelman AM. Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: steps 2 and 3. J Lipid Res. 2000;41:1495-1508.
36. The Expert Panel. Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Arch Intern Med. 1988;148:36-69.
37. National Cholesterol Education Program. Second Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). Circulation. 1994;89:1333-1445.
38. National Reference System for Cholesterol. Cholesterol Reference Method Laboratory Network. Available at: http://www.cdc.gov/labstandards/crmln.htm. Accessed May 28, 2008.
39. Marcovina SM, Albers JJ, Kennedy H, Mei JV, Henderson LO, Hannon WH. International Federation of Clinical Chemistry standardization project for measurements of apolipoproteins A-I and B, IV: comparability of apolipoprotein B values by use of international reference material. Clin Chem. 1994;40:586-592.